Pragmatic Welcomes HRH The Princess Royal to Pragmatic Park for the Opening of the UK's First 300mm Semiconductor Wafer Manufacturing Facility
27.3.2024 14:13:00 EET | Business Wire | Press release
Today, Pragmatic Semiconductor was honoured to welcome HRH The Princess Royal to officially open the UK’s first 300mm semiconductor wafer fabrication line (fab) at Pragmatic Park in Durham. The advanced manufacturing facility produces chips based on Pragmatic’s innovative and unique flexible integrated circuit technology. HRH The Princess Royal was hosted by David Moore, CEO, Pragmatic Semiconductor, with a tour of the clean room and facilities, followed by an unveiling of a site plaque to mark the occasion. Attendees included key customers, ecosystem partners, investors and government officials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327583783/en/
The UK’s first 300mm semiconductor fabrication line at Pragmatic Park, Durham, UK (Photo: Business Wire)
Pragmatic’s FlexICs are low-cost, more sustainable alternatives to silicon chips, ultra-thin, with a flexible form factor they enable connect, sense and compute capabilities, fuelling the Internet of Things (IoT) across multiple sectors including consumer, industrial, healthcare and beyond. The company’s mission is to provide item level intelligence to trillions of smart objects over the next decade across a wide range of applications with significant opportunities in smart packaging of fast-moving consumer goods that will significantly improve levels of reuse and recycling, transforming waste management, and enabling a circular economy. Other use cases include wearables, sensors and flexible controllers.
Pragmatic Park has capacity to host up to nine fabrication lines, each capable of producing billions of chips per year. Pragmatic’s pioneering sustainable approach extends to its manufacturing, using fewer process steps and a more concentrated footprint, than standard silicon fabs. The company’s innovative, optimised manufacturing process supports extremely rapid production cycles of less than 48 hours, at very low cost. The manufacturing process also uses significantly less energy and less water than typical silicon manufacturing, and fewer harmful gases. Pragmatic’s modular ‘Fab-in-a-Box’ approach, supports co-location of end-to-end FlexIC manufacturing at customers sites, rationalising extended supply chains and providing additional levels of security and resilience. The manufacturing facility enables the company to meet the growing demand for its unique technology from customers worldwide. Over the next five years Pragmatic anticipates creating over 500 highly skilled jobs in the North-East of England and Cambridge.
Dave Moore, CEO, Pragmatic Semiconductor said: "Today’s official opening marks a key milestone in Pragmatic’s growth trajectory and for the UK on the global semiconductor stage. I am incredibly proud of what the team has achieved and the ambition of our mission to enable item level intelligence in over a trillion sustainable, smart items over the next decade. Such intelligence at scale has the power to accelerate the digital transformation across industries. Sustainability is at the very core of our technology and extends to how FlexICs enable our customers to further drive innovations and pathways through their products and services towards global net zero goals.”
Francisco Melo, President Solutions Group, Avery Dennison said: “The key to any effective collaboration is a shared mindset. Pragmatic’s innovative approach is reflective of our own, as is its commitment to helping solve business challenges. The opening of an advanced manufacturing chip facility is fantastic news for all technology innovators. Congratulations to Pragmatic on such an important and impressive achievement. I look forward to our clients harnessing the potential of Pragmatic's flexible integrated circuits as part of our evolving inlay portfolio."
Simon Little, Banking & Investments Director, UKIB and Pragmatic Board member said: “The Bank invested in Pragmatic to support low carbon domestic manufacturing of semiconductors in the UK. The official opening of Pragmatic Park in Durham marks a pivotal next step in its journey, and we look forward to seeing the long-term impact of our investment, as Pragmatic scales up its operation and creates highly skilled jobs here in the North-East.”
Niranjan Sirdeshpande, Global Head of M&G’s Catalyst strategy and Pragmatic Board member said: “The UK has a very supportive ecosystem for providing early-stage funding, but it becomes challenging for businesses looking for later stage capital. By providing growth equity to enterprising tech disruptors such as Pragmatic, M&G’s £5 billion Catalyst strategy can help them to scale, provide expertise and partner with them all the way to success. Put to work in this way, patient capital can support economic growth and capture value for peoples' pensions and savings as we transition to a more sustainable economy. We are proud to support Pragmatic’s work in Durham with tech advancement in this critical part of the UK's national infrastructure.”
About Pragmatic Semiconductor
Pragmatic is revolutionising semiconductor fabrication with ultra-low-cost, flexible integrated circuit (FlexIC) technology that makes it quick and easy to embed intelligence almost anywhere.
With rapid cycle times that substantially accelerate time to market, its foundry provides high-volume fabrication at a fraction of the cost of silicon, with a significantly lower environmental impact.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327583783/en/
Contact information
Helen Ledger, SVP of Corporate Marketing, Communications and Public Affairs, PR@pragmaticsemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
